shares of reviva pharmaceuticals holdings inc on monday rose after the pharmaceutical company said its phase 3 trial for its antipsychotic brilaroxazine continues to progress well with over 30 enrolled in the us at 1140 edt shares of reviva pharmaceuticals were up 12 at 425 a share the company said brilaroxazine the drug aimed at treating schizophrenia also has enrollment across sites in europe additionally there is planned initiation of multiple sites in india before the year ends the companys chief executive laxminarayan bhat said no treatmentrelated serious adverse events or major safety and tolerability concerns have been observed to date in this doubleblind phase 3 study we remain highly encouraged by the potential for brilaroxazine mr bhat said schizophrenia afflicts about 24 million people worldwide the company said